CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Receives Consensus Rating of "Buy" from Analysts

Retrieved on: 2020-12-12 06:15:59

Tags for this article:

Click the tags to see associated articles and topics

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Receives Consensus Rating of "Buy" from Analysts. View article details on hiswai:

Excerpt

Schonfeld Strategic Advisors LLC now owns 501,368 shares of the biopharmaceutical company's stock worth $3,630,000 after buying an additional ...

Article found on: www.marketbeat.com